Kyverna Therapeutics Inc (KYTX) Stock Price, Quote & News

Company Profile

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product cand...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 925 2492

Website: kyvernatx.com

Address:

5980 Horton Street, Suite 550, Emeryville, United States

hummer2277 May. 15 at 7:15 PM

$KYTX investor meeting next Tues

0 · Reply

Thrasher5699 May. 15 at 7:07 PM

$KYTX Down 12% in one trading session is pretty crazy. I bet we close around 9.80 there should be an end of day push

0 · Reply

Thrasher5699 May. 15 at 6:45 PM

$KYTX I'm not sure how you can watch those videos and not be completely amazed at what this company is doing!

0 · Reply

PeterMarksMD May. 15 at 6:43 PM

$KYTX Added 1,500. Holding ~9k.

2 · Reply

Thrasher5699 May. 15 at 6:34 PM

$KYTX I bought a ton today. I had to keep chasing to 9.40. LFG Holding 10k Shares

0 · Reply

FelixH86 May. 15 at 6:10 PM

$KYTX added...-)..

0 · Reply

hummer2277 May. 15 at 5:45 PM

$KYTX shaking for

0 · Reply

PeterMarksMD May. 15 at 5:16 PM

$KYTX Not even 1% of the float has been traded. Just noise.

0 · Reply

InsaneZane May. 15 at 5:14 PM

$KYTX they do this everytime. Look at the chart. It will bounce back next week.

0 · Reply

bioland May. 15 at 5:07 PM

$KYTX Bios are the canary in the coal mine...buckle up.

0 · Reply

Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright

May 14, 2026, 8:00 AM EDT - 3 days ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences

2026-05-13T11:20:39.000Z - 4 days ago

Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan

2026-05-12T22:38:44.000Z - 4 days ago

Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)

May 12, 2026, 4:02 PM EDT - 4 days ago

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

2026-05-04T12:45:05.000Z - 13 days ago

Kyverna Therapeutics appoints Nadia Dac as chief commercial officer

OMER

May 4, 2026, 8:00 AM EDT - 13 days ago

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

Apr 22, 2026, 7:00 AM EDT - 25 days ago

Kyverna Therapeutics Transcript: Status update

2026-04-21T22:50:16.000Z - 25 days ago

Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel

Apr 21, 2026, 6:45 PM EDT - 25 days ago

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

2026-04-20T13:12:24.000Z - 27 days ago

Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel

Apr 20, 2026, 8:00 AM EDT - 27 days ago

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Apr 9, 2026, 8:00 AM EDT - 5 weeks ago

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

2026-03-26T20:25:22.000Z - 7 weeks ago

Kyverna Therapeutics files $300M mixed securities shelf

2026-03-26T20:12:42.000Z - 7 weeks ago

Kyverna Therapeutics reports Q4 EPS (80c), consensus (86c)

Mar 26, 2026, 4:02 PM EDT - 7 weeks ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 9, 2026, 11:20 AM EDT - 2 months ago

Kyverna Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 4:21 PM EST - 2 months ago

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Mar 3, 2026, 8:00 AM EST - 2 months ago

Kyverna Therapeutics to Participate in Upcoming March Investor Conferences

2026-02-24T13:20:34.000Z - 2 months ago

Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board

BEAM

Feb 24, 2026, 8:00 AM EST - 2 months ago

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

2026-02-03T13:25:38.000Z - 3 months ago

Kyverna Therapeutics appoints Pujols as Chief Technology Officer

Feb 3, 2026, 8:00 AM EST - 3 months ago

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

Jan 14, 2026, 12:45 PM EST - 4 months ago

Kyverna Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T13:38:56.000Z - 4 months ago

Kyverna Therapeutics provides corporate update, priorities for 2026

Jan 12, 2026, 8:00 AM EST - 4 months ago

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 4 months ago

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

2025-12-17T14:30:20.000Z - 5 months ago

Kyverna prices 13.3M shares at $7.50 in underwritten public offering

Dec 17, 2025, 9:24 AM EST - 5 months ago

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

2025-12-16T11:51:24.000Z - 5 months ago

Kyverna Therapeutics price target raised to $33 from $31 at Wells Fargo

2025-12-15T21:05:21.000Z - 5 months ago

Kyverna Therapeutics offers to sell $100M in common stock

Dec 15, 2025, 4:01 PM EST - 5 months ago

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

2025-12-15T20:10:09.000Z - 5 months ago

Leerink raises Kyverna price target, says KYSA-8 study results transformative

2025-12-15T19:30:14.000Z - 5 months ago

Kyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley

Dec 15, 2025, 8:00 AM EST - 5 months ago

Kyverna Therapeutics Transcript: Study Result

Dec 15, 2025, 6:42 AM EST - 5 months ago

Kyverna's cell therapy meets main goal of mid-stage study

Dec 15, 2025, 6:30 AM EST - 5 months ago

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Dec 14, 2025, 2:30 PM EST - 5 months ago

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Nov 17, 2025, 8:00 AM EST - 6 months ago

Kyverna Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:05 PM EST - 6 months ago

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 6 months ago

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2025, 8:00 AM EST - 6 months ago

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Oct 29, 2025, 8:00 AM EDT - 7 months ago

Kyverna Therapeutics Transcript: Study Update

Oct 29, 2025, 6:30 AM EDT - 7 months ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Oct 25, 2025, 11:00 AM EDT - 7 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Oct 22, 2025, 8:00 AM EDT - 7 months ago

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Sep 24, 2025, 9:05 AM EDT - 8 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Sep 15, 2025, 1:02 PM EDT - 8 months ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Sep 9, 2025, 11:00 AM EDT - 8 months ago

Kyverna Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:05 PM EDT - 8 months ago

Kyverna Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 11:00 AM EDT - 9 months ago

Kyverna Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 28, 2025, 11:00 AM EDT - 9 months ago

Kyverna Therapeutics Transcript: KOL Event

Aug 28, 2025, 8:00 AM EDT - 9 months ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Aug 25, 2025, 4:02 PM EDT - 9 months ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Aug 12, 2025, 4:02 PM EDT - 9 months ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 8:30 AM EDT - 10 months ago

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

Jun 4, 2025, 4:55 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 13, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Mar 27, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 3, 2025, 4:05 PM EST - 1 year ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 7, 2025, 11:42 AM EST - 1 year ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

hummer2277 May. 15 at 7:15 PM

$KYTX investor meeting next Tues

0 · Reply

Thrasher5699 May. 15 at 7:07 PM

$KYTX Down 12% in one trading session is pretty crazy. I bet we close around 9.80 there should be an end of day push

0 · Reply

Thrasher5699 May. 15 at 6:45 PM

$KYTX I'm not sure how you can watch those videos and not be completely amazed at what this company is doing!

0 · Reply

PeterMarksMD May. 15 at 6:43 PM

$KYTX Added 1,500. Holding ~9k.

2 · Reply

Thrasher5699 May. 15 at 6:34 PM

$KYTX I bought a ton today. I had to keep chasing to 9.40. LFG Holding 10k Shares

0 · Reply

FelixH86 May. 15 at 6:10 PM

$KYTX added...-)..

0 · Reply

hummer2277 May. 15 at 5:45 PM

$KYTX shaking for

0 · Reply

PeterMarksMD May. 15 at 5:16 PM

$KYTX Not even 1% of the float has been traded. Just noise.

0 · Reply

InsaneZane May. 15 at 5:14 PM

$KYTX they do this everytime. Look at the chart. It will bounce back next week.

0 · Reply

bioland May. 15 at 5:07 PM

$KYTX Bios are the canary in the coal mine...buckle up.

0 · Reply

blocktrade May. 15 at 4:59 PM

$KYTX HC Wainwright raised their pt from 20-25 today and it’s down 11%. 👍🙄

1 · Reply

bioland May. 15 at 4:16 PM

$KYTX Crickets here today....LOL

1 · Reply

Th3M4skedSt0nker May. 14 at 6:01 AM

$KYTX yeah, especially one and five year chart reads like a blueprint for a successful bio turnaround story...this will continue to climb much further within the current uptrend corridor during 2026/2027 and beyond 💲📈

0 · Reply

vu_jade May. 14 at 4:08 AM

$KYTX nice looking chart

1 · Reply

HeavyFt May. 14 at 12:03 AM

$KYTX $6 pullback still possible on the market instability

2 · Reply

HarryScrotmmm May. 13 at 10:11 PM

$KYTX JPM keeps Outperform and lowers target from 30 to 29. LOL why even

2 · Reply

PeterMarksMD May. 13 at 8:09 PM

$KYTX Like your mum.

0 · Reply

hummer2277 May. 13 at 8:09 PM

$KYTX funds are quietly buying

0 · Reply

Th3M4skedSt0nker May. 13 at 1:56 PM

$KYTX they will start earning some dollar by eoy with SPS and will develop into a fully fledged autoimmune CAR-T Therapy Platform This is gold standard biotech blue sky potential

1 · Reply

Th3M4skedSt0nker May. 13 at 1:54 PM

$KYTX will be $30-$50 this year with a little more retail love 💲❤️💲❤️💲

0 · Reply

peapope May. 13 at 1:48 PM

$KYTX $20 stock in a year

0 · Reply

Market Cap	576.94M
Revenue (ttm)	0.00
Net Income (ttm)	-161.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.11

Volume	1,195,400
Avg Vol	961,922
Day's Range	N/A - N/A
Shares Out	60.80M
Stochastic %K	25%
Beta	2.05
Analysts	Strong Sell
Price Target	$29.40